The result suggests that the protein made by the gene, known as Nwd1, and other molecules it interacts with could be ...

Madrigal Pharmaceuticals' Rezdiffra had a strong launch with $103.3M in Q4 sales and solid liquidity. See why I have a ...

CONSHOHOCKEN, PA — Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) has announced the appointment of Jacqualyn (“Jackie”) Fouse, ...

Madrigal's Rezdiffra showed significant liver stiffness reduction in MASH cirrhosis. The company also beat Q4 earnings and revenue expectations.

The price you pay for Rezdiffra may depend on factors such as your dosage, whether you have health insurance, and the pharmacy you use. Financial assistance may be available to help you with the ...

The safety and tolerability profile of Rezdiffra in the trial was consistent with previous studies, showing a low rate of discontinuations due to adverse events. Madrigal plans to present ...

Dr. Fouse expressed excitement about joining Madrigal and contributing to its mission, particularly following the launch of their first FDA-approved treatment for MASH, Rezdiffra. Appointment of ...

Fred Craves, Ph.D. to retire from Madrigal’s Board of Directors in July 2025CONSHOHOCKEN, Pa., March 11, 2025 (GLOBE NEWSWIRE) -- Madrigal ...

Reports Q4 revenue $103.3M, consensus $97.81M. Bill Sibold, Chief Executive Officer of Madrigal, stated, “Looking back on 2024, I’m incredibly ...

Madrigal Pharmaceuticals Inc (MDGL) reports robust financial performance with significant milestones in Rezdiffra's launch and market penetration.

I look forward to working with her to drive the launch of Rezdiffra, expand geographically, advance our clinical program in compensated MASH cirrhosis, and build our pipeline. I’d also like to ...

On Wednesday, Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) reported two-year results from the open-label compensated MASH cirrhosis (F4c) arm of the Phase 3 MAESTRO-NAFLD-1 trial of Rezdiffra ...